Barclays’s Aldeyra Therapeutics ALDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$367K Buy
95,648
+44,691
+88% +$171K ﹤0.01% 3198
2025
Q1
$293K Sell
50,957
-24,373
-32% -$140K ﹤0.01% 3139
2024
Q4
$376K Buy
75,330
+9,769
+15% +$48.8K ﹤0.01% 3212
2024
Q3
$353K Buy
65,561
+48,313
+280% +$260K ﹤0.01% 3181
2024
Q2
$57K Sell
17,248
-15,239
-47% -$50.4K ﹤0.01% 3619
2024
Q1
$106K Sell
32,487
-31,368
-49% -$102K ﹤0.01% 3619
2023
Q4
$224K Sell
63,855
-74,456
-54% -$261K ﹤0.01% 3455
2023
Q3
$924K Buy
138,311
+11,447
+9% +$76.5K ﹤0.01% 2142
2023
Q2
$1.07M Buy
126,864
+110,039
+654% +$924K ﹤0.01% 2109
2023
Q1
$167K Sell
16,825
-12,954
-44% -$129K ﹤0.01% 3251
2022
Q4
$207K Buy
29,779
+20,844
+233% +$145K ﹤0.01% 3072
2022
Q3
$48K Buy
+8,935
New +$48K ﹤0.01% 3665
2022
Q2
Sell
-150,981
Closed -$671K 4686
2022
Q1
$671K Buy
150,981
+92,072
+156% +$409K ﹤0.01% 2596
2021
Q4
$236K Buy
58,909
+15,028
+34% +$60.2K ﹤0.01% 2780
2021
Q3
$386K Buy
43,881
+15,186
+53% +$134K ﹤0.01% 2708
2021
Q2
$325K Sell
28,695
-22,050
-43% -$250K ﹤0.01% 2680
2021
Q1
$603K Buy
+50,745
New +$603K ﹤0.01% 2564
2020
Q3
Sell
-6,451
Closed -$27K 3714
2020
Q2
$27K Sell
6,451
-1,170
-15% -$4.9K ﹤0.01% 3521
2020
Q1
$19K Sell
7,621
-15,305
-67% -$38.2K ﹤0.01% 3389
2019
Q4
$133K Buy
22,926
+11,737
+105% +$68.1K ﹤0.01% 3352
2019
Q3
$59K Sell
11,189
-3,352
-23% -$17.7K ﹤0.01% 3623
2019
Q2
$87K Buy
14,541
+6,342
+77% +$37.9K ﹤0.01% 3650
2019
Q1
$74K Buy
8,199
+1,759
+27% +$15.9K ﹤0.01% 3470
2018
Q4
$53K Buy
6,440
+73
+1% +$601 ﹤0.01% 3155
2018
Q3
$88K Buy
6,367
+5,199
+445% +$71.9K ﹤0.01% 3484
2018
Q2
$9K Buy
1,168
+1,167
+116,700% +$8.99K ﹤0.01% 3915
2018
Q1
$0 Buy
+1
New ﹤0.01% 4180
2017
Q4
Sell
-3,400
Closed -$24K 4056
2017
Q3
$24K Buy
+3,400
New +$24K ﹤0.01% 3159